PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry
Amish J. Patel,Sarah Warda,Jesper L.V. Maag,Rohan Misra,Mohini R. Pachai,Cindy J. Lee,Dan Li,Naitao Wang,Gabriella Bayshtok,Eve Fishinevich,Yinuo Meng,Elissa W.P. Wong,Juan Yan,Emily Giff,Melissa B. Pappalardi,Michael T. McCabe,Jonathan A. Fletcher,Charles M. Rudin,Sarat Chandarlapaty,Joseph M. Scandura,Richard P. Koche,Jacob L. Glass,Cristina R. Antonescu,Deyou Zheng,Yu Chen,Ping Chi,Miguel A. Miranda-Roman
DOI: https://doi.org/10.1158/2159-8290.cd-21-1671
IF: 28.2
2022-07-06
Cancer Discovery
Abstract:Polycomb Repressive Complex 2 (PRC2) has oncogenic and tumor suppressor roles in cancer. There is clinical success of targeting this complex in PRC2-dependent cancers, but an unmet therapeutic need exists in PRC2-loss cancer. PRC2 inactivating mutations are a hallmark feature of high-grade malignant peripheral nerve sheath tumor (MPNST), an aggressive sarcoma with poor prognosis and no effective targeted therapy. Through RNAi screening in MPNST, we found that PRC2-inactivation increases sensitivity to genetic or small molecule inhibition of DNA methyltransferase 1 (DNMT1), which results in enhanced cytotoxicity and antitumor response. Mechanistically, PRC2 inactivation amplifies DNMT inhibitor (DNMTi) mediated expression of retrotransposons, subsequent viral mimicry response, and robust cell death in part through PKR-dependent double stranded-RNA (dsRNA) sensor. Collectively, our observations posit DNA methylation as a safeguard against anti-tumorigenic cell fate decisions in PRC2-loss cancer to promote cancer pathogenesis, which can be therapeutically exploited by DNMT1 targeted therapy.
oncology